Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 24-33

  Zhu, MingZhu ^a   Marshall, John ^b   Cole, David ^c   Schlom, Jeffrey ^a   Tsang, Kwong Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FOWLPOX VIRUS; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL LINE; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0033973608     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Peace, D. J., Chen, W., Nelson, H., and Cheever, M. A. T-cell recognition of transforming proteins encoded by mutated ras protooncogenes. J. Immunol., 146: 2059-2065, 1991.
2. Jung, S., and Schluesener, H. J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras protein. J. Exp. Med., 173: 273-276, 1991.
3. Tsang, K. Y., Nieroda, C. A., DeFilippi, R., Chung, Y. K., Yamaue, H., Greiner, J. W., and Schlom, J. Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res., 3: 183-193, 1994.
4. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
5. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170: 246-252, 1994.
6. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
7. Kawakami, Y., Eliyahu, S., Sakaguchi K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Method, 180: 347-352, 1994.
8. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol., 154: 3961-3968, 1995.
9. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwuck, R., Humblet, Y., Canon, J-L., Laurent, C., Naeyaert, J-M., Plagne, R., Deraemaeker, R., Knuth, A., Jager, E., Brasseur, F., Herman J., Coulie, P. G., and Boon, T. Tumor regression responses in melanoma patients treated with a peptide encoded by MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
10. Morioka, N., Kikumoto, Y., Hoon, D. S., Morton, D. L., and Irie, R. F. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol. Immunol., 32: 573-581, 1995.
11. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitrou, J., McKenzie, I. F. C., Bast, R. C., and Finn, O. J. Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51: 2908-2916, 1991.
12. Tilkin, A-F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M-C., Lefrere, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J-G., and Bressec-de Paillerets, B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol., 25: 1765-1769, 1995.
13. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 17: 432-436, 1995.
14. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigens. J. Natl. Cancer Inst., 89: 293-300, 1997.
15. Hamilton, J. M., Chen, A. P., Nguyen, B., Grem, J., Abrams, S., Chung, Y., Kantor, J., Phares, J. C., Bastian, A., Brooks, C., Morrison, G., Allegra, C. J., and Schlom, J. Phase I study of recombinant vaccinia virus (rV) that expresses human carcinoembryonic antigen (CEA) in adult patients with adenocarcinomas. Proc. Am. Soc. Clin. Oncol., 13: 295, 1994.
16. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
17. Pincus, S., Tartaglia, J., and Paoletti, E., Poxvirus-based vectors as vaccine candidates. Biologicals, 23: 159-164, 1995.
18. Esposito, J. J. Poxviridiae. In: R. I. B. Francki, C. M. Fauquet, D. L. Knudson, and F. Brown (eds.), Classification and Nomenclature of Viruses, pp. 91-102. New York: Springer Verlag, 1991.
19. Taylor, J., Weinberg, R., Languet, B., Desmettre, P., and Paoletti, E. A recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine, 6: 497-503, 1988.
20. Taylor, J., Trimarchi, C., Weinberg, R., Languet, B., Guillemin, F., Desmettre, C., and Paoletti, E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine, 9: 190-193, 1991.
21. Tartaglia, J., Jarrett, O., Neil, J. C., Desmettre, P., and Paoletti, E. Protection of cats against feline leukemia virus by vaccination with canarypox virus recombinant ALVAC-FL. J. Virol., 67: 2370-2375, 1993.
22. Konishi, E., Pincus, S., Paoletti, E., Shope, R. E., and Mason, P. W. Avipox virus-vectored Japanese encephalitis virus vaccine: use as vaccine candidate in combination with purified subunit immunogens. Vaccine, 12: 633-638, 1994.
23. Gonozol, E., Berencsi, K., Pincus, S., Endresz, V., Meric, C., Paoletti, E., and Plotkin, S. A. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine, 13: 1080-1085, 1995.
24. Taylor, J., Meignier, B., Tartaglia, J., Languet, B., VanderHoeven, J., Franchini, G., Trimarchi, C., and Paoletti, E. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (rCP65) in non-avian species. Vaccine, 13: 539-549, 1995.
25. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian poxvirus to enhance T-cell immunity and antitumor responses. Vaccine, 15: 759-768, 1997.
26. Cadoz, M., Strady, A., Meignier, B., Taylor, J., Tartaglia, J., Paoletti, E., and Plotkin, S. Immunization with canarypox virus expressing rabies glycoprotein. Lancet, 339: 1429-1432, 1992.
27. Cox, W. I., Tartaglia, J., and Paoletti, E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-I envelope glycoprotein. Virology, 195: 845-850, 1993.
28. Marshall, J. L., Hawkins, M., Tsang, K-Y., Richmond, E., Pedicano, J., Zhu, M-Z., and Schlom, J. A Phase I study in cancer patients of a replication-defective avipox (ALVAC) recombinant vaccine that expresses human carcinoembryonic antigen (CEA). J. Clin. Oncol., 17: 332-337, 1999.
29. Storkus, W. J., Howell, D. N., Salter, R. D., Dawson, J. R., and Cresswell, P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol., 138: 1657-1659, 1987.
30. Hogan, K. T., Shimojo, N., Walk, S. F., Engelhard, V. H., Maloy, W. L., Coligan, J. E., and Biddison, W. E. Mutations in the α2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J. Exp. Med., 168: 725-736, 1988.
31. Boyüm, A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood: general sedimentation properties of white blood cells in a 1 g gravity field. Scand. J. Clin. Lab. Investig., 97 (Suppl.): 51-76, 1968.
32. Guadagni, F., Witt, P. L., Robbins, P. F., Schlom, J., and Greiner, J. W. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-γ. Cancer Res., 50: 6248-6255, 1990.
33. Chomczynski, P., and Sacci, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1994.
34. Nishimura, M. I., Kawakami, Y., Charmley, P., O'Neil, B., Shilyansky, J., Yannelli, J. R., Rosenberg, S. A., and Hood, L. T-cell receptor repertoire in tumor infiltrating lymphocytes: analysis of melanoma-specific long-term lines. J. Immunother., 16: 85-94, 1994.
35. Pannetier, C., Chocet, M., Darche, S., Casrouge, A., Zoller, M., and Kourilsky, P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ line segments. Proc. Natl. Acad. Sci. USA, 90: 4319-4325, 1993.
36. Sabzevari, H., Propp, S., Kono, D. H., and Theofilopoulos, A. N. G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus mice. Eur. J. Immunol., 27: 1901-1910, 1997.
37. Conry, R. M., Saleh, M. N., Schlom, J., and LoBuglio, A. F. Human immune response to carcinoembryonic antigen tumor vaccine. J. Immunother., 18: 137, 1995.
38. Zhu, M., Zaremba, S., Correale, P., Czartoski, T., Lora, M., Hamilton, J. M., Schlom, J., and Tsang, K. Y. Generation of specific anti-human carcinoembryonic antigen (CEA) cytotoxic T lymphocytes from a colon carcinoma patient immunized with recombinant vaccinia-CEA (rV-CEA) vaccine by stimulation with a CEA synthetic peptide (CAP2) in vitro. J. Immunother., 19: 459, 1996.
39. Bremers, A. J. A., van der Burg, S. H., Kuppen, P. J. K., et al. The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T lymphocyte epitopes. J. Immunother., 18: 77-85, 1995.
40. Nukaya, I., Yasumoto, M., Iwasaki, T., Ideno, M., Sette, A., Celis, E., Takesako, K., and Kato, I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int. J. Cancer, 80: 92-97, 1999.
41. Tsang, K. Y., Zhu, M. Z., Nieroda, C. A., Correale, P., Zaremba, S., Hamilton, J. M., Cole, D., Lam, C., and Schlom, J. Phenotypic stability of a cytotoxic T cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin. Cancer Res., 3: 2439-2449, 1997.
42. Sensi, M., Traversan, C., Radrizzani, M., Salvi, S., Maccalli, C., Mortarini, R., Rivoltini, L., Farina, C., Nicolini, G., Wolfel, T., Brichard, V., Boon, T., Bordingnon, C., Anichini, A., and Parmiani, G. Cytotoxic T lymphocyte clones from different patients display limited T-cell receptor variable gene usage in HLA-A2-restricted recognition of Melan A/Mart-1 melanoma antigen. Proc. Natl. Acad. Sci. USA, 92: 5674-5678, 1995.
43. Cole, D. J., Weil, D. P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., Jennings, C., Eliyahu, S., Rosenberg, S. A., and Mishimura, M. I. Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res., 54: 5265-5268, 1994.
44. Philip, R., Brunette, E., Ashton, J., Alters, S., Gadea, J., Sorich, M., Yau, J., O'Donoghue, G., Lebowski, J., Okarma, T., and Philip, M. Transgene expression in dendritic cells to induce antigen-specific cytotoxic T cells in healthy donors. Cancer Gene Ther., 5: 236-246, 1998.
45. Mackay, C. R., and Imhof, B. A. Cell adhesion in the immune system. Immunol. Today, 14: 99-102, 1993.
46. Fagerberg, J., Samanci, A., Yi, Q., Strigard, K., Ryden, U., Wahren, B., and Mellstedt, H. Recombinant carcinoembryonic antigen and granulocyte-macrophage-colony stimulating factor for active immunization of colorectal carcinoma patients. J. Immunother., 19: 461, 1996.
47. Philip, R., Brunette, E., Alter, S., Gadea, J., Zheng, H., Yau, J., Lebkowski, J., and Philip, M. Gene-modified and peptide-pulsed dendritic cells for the generation of active immunotherapy strategies. J. Immunother., 19: 467, 1996.
48. Mehta, D. A., Markowicz, S., and Engleman, E. Generation of antigen-specific CD8+ CTLs from native precursors. J. Immunol., 153: 996-1003, 1994.
49. Alters, S. E., Gadea, J. R., Sorich, M., O'Donoghue, G., Talib, S., and Philip, R. Dendritic cells pulsed with CEA peptide induced CEA-specific CTL with restricted TCR repertoire. J. Immunother., 21: 17-26, 1998.
50. Kim, C. J., Prevette, T., Cormier, J., Overwijk, W., Roden, M., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Dendritic cells infected with pox virus encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother., 20: 276-286, 1997.